Reverse Mergers Say Hey as Biotechs Trade Low, Hunt for Alternatives and Launch Few IPOs

Cooley partner Richard Segal was quoted in Endpoints News on current trends in the biotechnology industry, such as reverse mergers and initial public offerings.

Read the article (subscription required)